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Background: Multiple sclerosis (MS) and epilepsy are both fairly common and it follows that they may sometimes
occur together in the same people by chance. We sought to determine whether hospitalisation for MS and
hospitalisation for epilepsy occur together more often than expected by chance alone.
Methods: We analysed two datasets of linked statistical hospital admission records covering the Oxford Record
Linkage Study area (ORLS, 1963–1998) and all England (1999–2011). In each, we calculated the rate of occurrence of
hospital admission for epilepsy in people after admission for MS, compared with equivalent rates in a control
cohort, and expressed the results as a relative risk (RR).
Results: The RR for hospital admission for epilepsy following an admission for MS was significantly high at 4.1 (95%
confidence interval 3.1–5.3) in the ORLS and 3.3 (95% CI 3.1–3.4) in the all-England cohort. The RR for a first
recorded admission for epilepsy 10 years and more after first recorded admission for MS was 4.7 (2.8–7.3) in ORLS
and 3.9 (3.1–4.9) in the national cohort. The RR for the converse–MS following hospitalisation for epilepsy–was 2.5
(95% CI 1.7–3.5) in the ORLS and 1.9 (95% CI 1.8–2.1) in the English dataset.
Conclusions: MS and epilepsy occur together more commonly than by chance. One possible explanation is that an
MS lesion acts as a focus of an epileptic seizure; but other possibilities are discussed. Clinicians should be aware of
the risk of epilepsy in people with MS. The findings may also suggest clues for researchers in developing
hypotheses about underlying mechanisms for the two conditions.
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Multiple sclerosis (MS) is one of the commonest serious
neurological conditions, with a prevalence of 0.1%, and
is caused by focal demyelination of the brain. Epilepsy is
also a common chronic neurological condition, with a
prevalence of approximately 0.5% of the population, and
is caused by abnormal electrical activity in the brain [1].
It is well known that focal lesions, such as tumours,
haemorrhages or abscesses, can act as a nidus for epileptic
seizures but there is a paucity of information on whether
the focal lesions caused by MS can cause epilepsy.* Correspondence: michael.goldacre@dph.ox.ac.uk
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reproduction in any medium, provided the orAlthough there have been studies examining the link be-
tween these two conditions, [2-6] which show an increase
in the prevalence of epilepsy following a diagnosis of MS,
most have been small. Any association between the two
conditions is not well understood or widely recognised.
This study used two large record-linked statistical
datasets, one for the Oxford region of England (from
1963–1998) and one for the whole of England (from
1999–2011), to determine whether MS and epilepsy co-
occur in the same individuals more commonly than ex-
pected by chance. We used both datasets to determine
whether there was consistency between them in the
findings.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Population and data
We used data from English national Hospital Episode
Statistics (HES, 1999–February 2011), provided by the
NHS Information Centre (IC), and English national death
registration data provided by the Office for National
Statistics. We also used data from the Oxford Record
Linkage Study (ORLS) which spans 1963 to 1998. Both
HES and the ORLS include brief statistical abstracts of
all hospital admissions and day case care. In English
National Health Service (NHS) terminology, a day case
is a patient who is admitted to hospital but who does
not stay overnight. Both datasets also include data from
death registrations. In each dataset, the abstracts for
each individual are linked together into a cumulative
record of successive hospital admissions, and death if it
occurred, for each person. The population covered by
the ORLS expanded from 850,000 people in years
preceding 1974 to 1.9 million from 1975–1988, and 2.5
million people from 1989 onwards. The population of
England is 55 million. The building of the linked data-
sets was done by staff of the Oxford Record Linkage
Study at the Unit of Health-Care Epidemiology, University
of Oxford. All data were anonymised by encryption of
identifiers; and the encrypted identifiers were used to link
successive records for the same individual.Analysis
The same analysis was done for each of the diseases in
combination as described below for MS preceding epi-
lepsy. In each dataset, a cohort of people with a hospital
admission or record of day case care for MS (which we
termed the ‘exposure cohort’) was constructed by iden-
tifying the first admission, or episode of day case care,
for MS as a reason for hospital care (in any diagnostic
position on the hospital record) in an NHS hospital dur-
ing the study period. The International Classification of
Diseases (ICD) code used for MS was G35 in the tenth
revision of the International Classification of Diseases,
with equivalent codes in ICD 7, 8 and 9 in the ORLS. A
second cohort, to be used as a ‘control cohort’, was con-
structed by identifying the first admission for each indi-
vidual with various other, mainly minor medical and
surgical conditions (see Table footnotes), as used by us
in other studies of associations between diseases [7,8].
In this design, the standard epidemiological practice
was followed, when hospital controls are used, of using
a broad range of conditions, rather than relying on a
narrow range (in case the latter are themselves atypical
in their risk of subsequent disease). People were excluded
from the MS or control cohort if they had an admission
for epilepsy either before or at the same time as the
admission for MS or the control condition.We then searched the linked database for any subse-
quent record of epilepsy as the ‘outcome’ condition. We
used the ICD10 codes G40–G41 for epilepsy and their
ICD 7, 8 and 9 equivalents.
Statistical methods
We calculated rates of epilepsy using person-years. We
took ‘date of entry’ into each cohort – MS and control
cohort – as the date of first admission for MS, or control
condition, and ‘date of exit’ as the date of first record of
subsequent epilepsy, death, or the end of study (December
31 1998 for ORLS, February 28 2011 for England),
whichever was earliest. We calculated rates for epilepsy,
stratified and then standardised by age (in five-year age
groups), sex, calendar year of first recorded admission,
region of residence, and quintile of patients’ Index of
Deprivation score (as a measure of socio-economic status,
only available for the all-England dataset). We standar-
dised by using the combined MS and control cohorts as
the standard population. The stratum-specific rates of epi-
lepsy in the standard population were applied to the num-
ber of people in each stratum in the MS cohort,
separately, and then to those in the control cohort, to give
an observed (O) and expected (E) number of people with
epilepsy in each of the two cohorts. The relative risk of
epilepsy in the MS cohort, relative to that in the control
cohort, was calculated using the formula (OMS/EMS)/
(Ocontr/Econtr), where O is the observed and E the expected
number of cases of epilepsy in the MS and control co-
horts. These calculations, and the calculation for the
confidence interval for the relative risk and χ2 statistics
for its significance, were undertaken using standard
published statistical methods [9].
We then reversed the procedures and repeated the
analyses for epilepsy as the ‘exposure’ condition and MS
as the ‘outcome’. We excluded anyone who had an admis-
sion for MS prior to the first record of epilepsy. These
methods provided results without double-counting any
individual (i.e. no individual appears in both the MS-
epilepsy and the epilepsy-MS analyses).
The datasets are in the custodianship of the Unit of
Health-Care Epidemiology and are not freely available.
Ethical approval to construct, maintain, develop and
analyse the datasets has been obtained, on an ongoing
basis, from the Central and South Bristol Multi–Centre
Research Ethics Committee (04/Q2006/176).
Results
There were 3 913 people in the MS cohort in the ORLS
dataset and 85 772 in the all-England dataset. There
were 18 790 people in the epilepsy cohort in the ORLS
data and 520 203 in the all-England data. Table 1 shows
the age distribution in each cohort, in each dataset, and
the percentages in each age group who were female.
Table 1 Number (N) and percentage of people with multiple sclerosis or epilepsy in each age group, and percentage of













<15 0.3 (60.0) 0.1 (58.1) 23.3 (43.7) 8.8 (45)
15–34 26.7 (70.1) 12.4 (71.0) 24.2 (47.5) 19.3 (49)
35–54 45.2 (65.8) 45.4 (70.2) 18.7 (44.3) 25.6 (46)
5–64 15.4 (62.4) 21.6 (66.1) 9.6 (39.3) 12.9 (46)
65+ 12.4 (66.7) 20.5 (69.0) 24.3 (49.7) 33.4 (53)
Total 100.0 (66.5) 100 (69.2) 100.0 (45.8) 100 (49)
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Following hospital admission for MS, there was a sig-
nificantly high risk of subsequent hospital admission
for epilepsy in both datasets (Table 2). The relative
risk, comparing the MS cohort with the control cohort,
was 4.1 (95% confidence interval 3.14–5.27) in the
ORLS and 3.3 (3.14–3.40) in the all-England cohort
(Table 2).Admission for epilepsy followed by admission for MS
In the cohort of people with epilepsy, similarly, there
was an increased risk of MS: 2.5 (1.71–3.54) in the
ORLS and 1.9 (1.79–2.07) in the England cohort
(Table 2). The relative risks were higher in the ‘MSTable 2 Occurrence of epilepsy in people admitted with mult
with epilepsy: observed (O) and expected number (E) of case
compared with the control cohortb, with its 95% confidence
between the two conditions







1–4 years 16 4.3 3
5–9 years 14 3.2 4
10+ years 19 4.1 4





1–4 years 9 3.4 2
5–9 years 6 2.7 2
10+ years 9 4.2 2
Total 33 13.6 2
aAll analyses were undertaken initially within five-year age groups (and within the o
combined epilepsy and control cohorts) as the ‘standard’, to provide observed and
control cohort, within each stratum group. The stratum-specific observed and expe
all-ages total, adjusted for age in 5-year bands, time period in single calendar years
residence, in quintiles.
bConditions used in control cohort, with Office of Population, Censuses and Surveys
equivalent codes used for other coding editions): adenoidectomy (OPCS4 E20), tons
(Q10–Q11), hip replacement (W37–W39), knee replacement (W40–W42), squint (ICD
haemorrhoids (I84), upper respiratory tract infections (J00–J06), deflected septum, nas
inguinal hernia (K40), in-growing nail, toenail and other diseases of nail (L60), bunion (Mfollowed by epilepsy’ analysis than in the ‘epilepsy
followed by MS’ analysis (Table 2).
Time intervals and age-groups
Table 2 shows analyses subdividing the associations by
time interval between first recorded admission for MS
and first recorded admission for epilepsy. Relative risks
were similar at each time interval, whether short or long.
The risk was highest in the younger age groups (those
under 55 years, Table 3).
Analyses were also done separately for males and
females, and for records in which MS and epilepsy
were the main diagnosis (rather than recorded in any
part of the hospital admission record). Relative risks in
these subsets were similar to those presented here.iple sclerosis, and of multiple sclerosis in people admitted
s in each cohort, relative risk (RR)a in the exposure cohort
intervals (95% CI), and p values, by time intervals
(1963–1998) England (1999–2011)
RR (95% CI) p value O E RR (95% CI) p value
.6 (1.92–6.23) <0.001 574 370.0 1.6 (1.44–1.70) <0.001
.7 (2.12–6.08) <0.001 1194 251.0 4.9 (4.66–5.24) <0.001
.4 (2.41–7.48) <0.001 726 166.0 4.5 (4.20–4.88) <0.001
.7 (2.80–7.34) <0.001 86 22.8 3.9 (3.11–4.85) <0.001
.1 (3.14–5.27) <0.001 2580 809.7 3.3 (3.14–3.40) <0.001
.9 (1.29–5.67) 0.003 206 196.1 1.1 (0.91–1.21) 0.48
.7 (1.21–5.23) 0.006 394 154.0 2.8 (2.52–3.13) <0.001
.3 (0.82–5.09) 0.083 206 90.5 2.4 (2.10–2.83) <0.001
.2 (0.99–4.24) 0.034 19 9.9 2.0 (1.19–3.27) <0.005
.5 (1.71–3.54) 0.001 825 450.4 1.9 (1.79–2.07) <0.001
ther strata used), using the combined MS and control cohorts (or the
expected numbers within (1) the MS cohort (or epilepsy cohort) and (2) the
cted numbers in each cohort were then summed to give an age-standardised
, region of residence and deprivation score associated with patients’ area of
(OPCS) code edition 4 for operations and ICD10 code for diagnosis (with
illectomy (F34, F36), appendectomy (H01–H03), dilation and curettage
10 H49–H51), cataract (H25), otitis (H60–H67), varicose veins (I83),
al polyp (J33+J34.2), impacted tooth and other disorders of teeth (K00–K03),
20.1), internal derangement of knee (M23), contraceptive management (Z30).
Table 3 Occurrence of epilepsy in people admitted with multiple sclerosis, and of multiple sclerosis in people admitted
with epilepsy: observed (O) and expected number (E) of cases in each cohort, relative risk (RR)a in the exposure cohort
compared with the control cohortb, with its 95% confidence intervals (95% CI), and p values, by age group
Exposure
disease
Age at admission for
exposure disease (years)
ORLS (1963–1998) England (1999–2011)




30 3.8 8.0 (5.34–11.39) <0.001 358 99.3 3.7 (3.28–4.05) <0.001
35–44 15 3.6 4.2 (2.35–7.07) <0.001 587 159.0 3.9 (3.59–4.26) <0.001
45–54 11 3.3 3.4 (1.66–6.11) <0.001 780 237.0 3.6 (3.34–3.87) <0.001
55–64 4 1.9 2.1 (0.57–5.46) 0.247 508 173.0 3.1 (2.81–3.37) <0.001
65–74 1 2.0 0.5 (0.01–2.81) 0.728 253 98.2 2.6 (2.31–2.98) <0.001
75+ 1 0.6 1.7 (0.04–9.34) 0.894 94 52.0 1.8 (1.46–2.22) <0.001




10 6.3 1.6 (0.76–2.98) 0.203 176 79.6 2.4 (2.01–2.77) <0.001
35–44 8 2.6 3.2 (1.37–6.52) 0.002 202 96.2 2.2 (1.92–2.59) <0.001
45–54 9 2.3 4.2 (1.87–8.25) <0.001 214 111 2.1 (1.77–2.36) <0.001
55–64 3 1.8 1.7 (0.35–5.32) 0.569 110 81.3 1.4 (1.13–1.68) <0.001
65–74 3 0.5 6.8 (1.23–24.57) 0.006 83 48.2 1.8 (1.41–2.23) <0.001
75+ 0 0 40 33.6 1.2 (0.85–1.66) 0.298
Total 33 13.6 2.5 (1.71–3.54) <0.001 825 450.4 1.9 (1.79–2.07) <0.001
a, bsee footnotes Table 2.
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Because we do not have data on out-migration, we can-
not give precise estimates of absolute risk. However,
using the English population (in which out-migration is
less of an issue than with the Oxford population), we
can give an approximation. In the English cohort of 85
772 people with MS (Table 1), there were 2 580 who
had an admission for epilepsy (Table 2). This gives an
approximate absolute risk of epilepsy of 3% in people
with MS.Discussion
Main findings
In these large population-based studies we confirm that
there is a statistically significant association between MS
and epilepsy. The elevation of risk of epilepsy after MS
was 3- to 4-fold. It was highest in the youngest age groups.
The study also shows an association in the opposite
direction, though less strong, between admission for
epilepsy followed by a subsequent admission for MS.Comparisons with existing literature
Previous studies have reported that the risk of epilepsy
after MS is between three to six times higher than that
in people without MS [2-6]. One study showed that the
peak increase in epilepsy occurred between four and
seven years after the diagnosis of MS [10]. A review of
29 studies (covering a total of 389 patients with MS and
epilepsy), published in 2003, concluded that there is evi-
dence for an association between epilepsy and multiplesclerosis but suggested that the association may not be
one of MS causing epilepsy [11].
Our study covered a much larger population than previ-
ous studies (it reports on 2642 patients with a record of
epilepsy after MS, and 858 with an admission for MS after
an admission for epilepsy).
Our estimates of the absolute risk of 3.0% for epilepsy in
people with MS are slight underestimates, as described in
the Results, but are similar to findings of 3.5% previously
reported [12].
Possible mechanisms and implications
While an explanation of mechanisms behind these asso-
ciations is beyond the scope of this study, the literature
provides suggestions about some potential mechanisms.
Lebrun showed that the frequency of seizures correlates
with the number of flare-ups of MS [13]. Two papers by
Calabrese et al. report that patients with MS and epilepsy
show more severe cortical inflammation, and a higher
number of intracortical lesions, than those with MS alone
[14,15]. Waxman put forward the hypothesis that the ab-
normal sodium channel expression found in the neurones
of some patients with MS could play a role both in the ini-
tial development of MS and in the subsequent occurrence
of epilepsy [16]. These sodium channel abnormalities, if
they preceded the demyelinating changes of MS, could
also explain epilepsy preceding MS.
If an MS lesion acts as a focus of an epileptic seizure,
it might be expected that there would be a correlation
between the location of the lesion and the origin of the
seizure. However, as the datasets do not include a record
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seizure, a study would have to be specifically set up to
test this hypothesis.
The weaker relationship between prior epilepsy and
subsequent MS, as found in this study, has several possible
explanations. First, because the study is based on hospital
admissions, it is possible that some people will have had
clinical MS, and some will have had epilepsy, without
being admitted to hospital; and others will have had
admissions for either before the start of the datasets.
Thus, we cannot be sure about the sequence of the
temporal relationships. Nonetheless, it seems unlikely
that the high relative risks for epilepsy in people first
admitted 10 years and more after an admission for MS –
4.1 in the ORLS, 3.9 in England (Table 2) – could be
wholly explained by epilepsy that actually preceded MS.
It is also possible that, in a small proportion of
patients subsequently diagnosed with MS, seizures
were the first symptom of MS; one paper reports that
seizures were the initial clinical manifestation of MS in
10% of MS patients [17].
It is also possible that treatment of MS, or of epilepsy,
may affect the association between the two diseases; but
we had no treatment data to test this. Results of clinical
trials on management of MS with interferon were pub-
lished in early 1990s and we assume that this treatment
became more widely prescribed from the mid-1990s
onwards. It is worth noting that the RRs in the ORLS
(largely pre-interferon) and the all-England dataset
(post-interferon) were similar. Finally, there could be
underlying contributing factors that, independently,
increase a person’s risk of developing both MS and
epilepsy, which would be an interesting area for future
research.
The findings could have important implications for
clinicians, first, in needing to be aware of the risk of
epilepsy in people with MS, and, second, because status
epilepticus may cause sudden death. Clinicians may
wish to judge whether individual patients with MS, and
their relatives, should be told about epilepsy risk or
whether to spare them concerns about it. On the one
hand the risk is uncommon, although at 3% it is not rare
either. On the other, the clinician might wish to warn
and educate the patient with MS, and his/her family,
about what to do in the event of a seizure. The clinician
may particularly want to consider whether the patient
has any other risk factors for epilepsy, such as medication
and alcohol use, that would potentially exacerbate this
risk.
Strengths and weaknesses
The study is large and was undertaken in geographically
defined populations. The Oxford dataset covers just a
regional population but includes long duration offollow-up, whereas the English dataset is much larger in
size but with shorter follow-up periods. There are some
weaknesses in this study. It is confined to people who
received day case care or hospital admission, both for
the identification of MS and for epilepsy. Data are not
recorded on people who have left the area covered by
the ORLS dataset (or those who leave England), and it
has been assumed that the rates of outward migration
would be similar in people with MS, epilepsy, and the
control population. These are reasons for using a ‘control’
cohort from within the datasets. We did not have data on
the criteria used to diagnose either epilepsy or MS, or on
the type of seizures. We relied wholly on the available ICD
codes. Current privacy regulations in England preclude
the possibility of sampling records and checking codes
against diagnostic information in patients’ original case re-
cords. However, the fact that the findings from the present
very large study (e.g. the absolute risk of 3%) are similar to
the findings from much smaller studies based on clinical
diagnostic criteria [2,4,13] indicates that our findings are
likely to be reliable.
Changes in diagnostic imaging, in particular the
increased use of MRI, may have resulted in more cases of
MS being diagnosed in recent years, although it can be
assumed that this would affect both the study cohorts and
the control cohort equally. It is noteworthy that both data-
sets – covering different time periods in which there will
have been different regimes of investigation and treatment
gave similar results. As discussed above, we cannot be sure
about the temporal sequence of MS and epilepsy. It would
need a study of patients’ life-long full medical record to
determine which disease came first.
We did a sub-study of time intervals between MS and
epilepsy, and vice versa, to consider the possibility of
surveillance bias. This bias can occur when the fact of
being diagnosed with one condition increases the chance
that another condition is found, investigated and recorded
in the patient’s case record. If there were surveillance bias,
a relative risk would be expected that is highest at short
time intervals after the first diagnosis, and which declines
as the interval increases. This was not found: this indicates
that surveillance bias has had only a minimal role, if any,
and that, for some people, there may be a long latency
period between the onset of MS and the manifestation of
epilepsy.
Conclusions
This study is the largest of its kind so far and provides
strong evidence for a link, possibly bidirectional, between
MS and epilepsy. This could have important implications
for clinicians in needing to be aware of the risk of epilepsy
in people with MS. It also has implications for researchers
in developing and testing hypotheses about underlying
mechanisms for the two conditions.
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